健世科技-B(09877.HK)預計10月10日掛牌上市 引入先健科技為基石
格隆匯9月23日丨健世科技-B(09877.HK)發佈公吿，公司擬全球發售807.64萬股股份，其中香港發售股份80.8萬股，國際發售股份726.84萬股，另有15%超額配股權；2022年9月23日至9月29日招股，預期定價日為9月29日；發售價將為每股發售股份26.70-28.80港元，每手買賣單位200股，入場費約5818港元；中金公司及花旗為聯席保薦人；預期股份將於2022年10月10日於聯交所主板掛牌上市。
集團是一家立足中國的醫療器械公司，致力於開發用於治療結構性心臟病的介入產品。公司於2011年12月在中國成立。自此，集團開發出針對不同類型結構性心臟病(包括三尖瓣疾病、主動脈瓣疾病、二尖瓣疾病及心力衰竭)的一系列治療解決方案。集團的核心產品LuX-Valve是集團自主開發的第一代經導管三尖瓣置換系統，專為重度三尖瓣返流及高手術風險患者而設計。集團的另一款核心產品Ken-Valve為治療重度主動脈瓣返流(或合併主動脈瓣狹窄)而設計，其預期應對的患者羣體需求，遠遠大於適應症只有治療主動脈瓣狹窄的經導管主動脈瓣置換系統。根據弗若斯特沙利文的資料，經導管主動脈瓣置換市場是相對成熟的市場，有眾多商業化產品，包括截至最後可行日期全球有25款獲准商業化的主要經導管主動脈瓣置換產品及中國有九款獲准商業化的經導管主動脈瓣置換產品。集團亦正在開發另外八款具備先進技術的在研產品，針對不同類型瓣膜疾病及心力衰竭。
集團已與先健科技(01302.HK)訂立基石投資協議，據此，基石投資者已同意(在若干條件規限下)按發售價認購總額2000萬美元(或約1.57億港元)可購買的發售股份數目(向下調整至最接近每手200股股份的完整買賣單位)。假設發售價為27.75港元(即本招股章程所載指示性發售價範圍的中位數)，基石投資者認購的發售股份總數將為565.66萬股發售股份。
假設超額配股權未獲行使，按發售價每股發售股份27.75港元(即指示性價格範圍的中位數)計算，估計集團收取的全球發售所得款項淨額將約為1.544億港元。集團目前擬將該等所得款項淨額約65.0%分配予集團核心產品(即LuX-Valve及KenValve)的研發、製造及商業化；約25.0%將分配予產品管綫的其他在研產品(包括LuXValve Plus、KenFlex及二尖瓣產品)的研發、臨牀試驗及產品註冊；及約10.0%將用於營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
